A randomized, double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Analysis of health-related quality of life, neurocognition and seizures Meeting Abstract
| Authors: | Peters, K.; Mellinghoff, I.; van den Bent, M.; Blumenthal, D.; Touat, M.; Clarke, J.; Mendez, J.; Yust-Katz, S.; Mason, W.; Ducray, F.; Umemura, Y.; Nabors, L. B.; Holdhoff, M.; Hottinger, A.; Arakawa, Y.; Sepúlveda, J.; Wick, W.; Soffietti, R.; Perry, J.; Giglio, P.; de la Fuente, M.; Maher, E.; Bottomley, A.; Zhao, D.; Pandya, S.; Steelman, L.; Hassan, I.; Wen, P.; Cloughesy, T. |
| Abstract Title: | A randomized, double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Analysis of health-related quality of life, neurocognition and seizures |
| Meeting Title: | 28th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 25 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Nov 15-19 |
| Meeting Location: | Vancouver, Canada |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | v254 |
| End Page: | v255 |
| Language: | English |
| ACCESSION: | WOS:001115245401189 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/noad179.0978 |
| Notes: | Meeting Abstract: QOL-26 -- Source: Wos |
